Riverwater Partners LLC Has $2.55 Million Position in Anika Therapeutics, Inc. (NASDAQ:ANIK)

Riverwater Partners LLC boosted its holdings in shares of Anika Therapeutics, Inc. (NASDAQ:ANIK - Free Report) by 539.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 101,996 shares of the biotechnology company's stock after buying an additional 86,037 shares during the quarter. Anika Therapeutics comprises 1.3% of Riverwater Partners LLC's portfolio, making the stock its 15th biggest holding. Riverwater Partners LLC owned 0.70% of Anika Therapeutics worth $2,552,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Boston Partners bought a new position in shares of Anika Therapeutics in the 1st quarter valued at approximately $733,000. State Board of Administration of Florida Retirement System acquired a new position in shares of Anika Therapeutics during the 1st quarter worth about $198,000. Meros Investment Management LP grew its holdings in Anika Therapeutics by 25.0% in the 2nd quarter. Meros Investment Management LP now owns 212,714 shares of the biotechnology company's stock valued at $5,388,000 after buying an additional 42,587 shares during the last quarter. Stonepine Capital Management LLC increased its position in Anika Therapeutics by 171.4% in the 2nd quarter. Stonepine Capital Management LLC now owns 165,397 shares of the biotechnology company's stock worth $4,190,000 after buying an additional 104,448 shares during the period. Finally, Acadian Asset Management LLC lifted its holdings in shares of Anika Therapeutics by 25.8% during the first quarter. Acadian Asset Management LLC now owns 421,427 shares of the biotechnology company's stock worth $10,701,000 after buying an additional 86,436 shares during the last quarter. Institutional investors and hedge funds own 91.53% of the company's stock.

Wall Street Analyst Weigh In

Separately, Barrington Research reaffirmed an "outperform" rating and set a $37.00 target price on shares of Anika Therapeutics in a research report on Tuesday.

Anika Therapeutics Trading Down 0.1 %

ANIK traded down $0.03 on Thursday, hitting $24.51. 44,293 shares of the stock traded hands, compared to its average volume of 62,424. The business has a fifty day moving average price of $25.07 and a two-hundred day moving average price of $25.78. Anika Therapeutics, Inc. has a 52 week low of $18.08 and a 52 week high of $29.11. The firm has a market capitalization of $357.53 million, a PE ratio of -4.67 and a beta of 0.83.

Anika Therapeutics (NASDAQ:ANIK - Get Free Report) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($0.01) EPS for the quarter, missing analysts' consensus estimates of $0.23 by ($0.24). Anika Therapeutics had a negative net margin of 44.45% and a positive return on equity of 0.94%. The firm had revenue of $41.92 million during the quarter, compared to analyst estimates of $39.90 million. During the same quarter in the previous year, the company posted ($0.06) earnings per share. On average, equities research analysts forecast that Anika Therapeutics, Inc. will post -0.1 EPS for the current fiscal year.

Anika Therapeutics Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.